TY - JOUR T1 - Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation JF - Evidence Based Medicine JO - Evid Based Med SP - 43 LP - 43 DO - 10.1136/ebm.9.2.43 VL - 9 IS - 2 A2 - , Y1 - 2004/03/01 UR - http://ebm.bmj.com/content/9/2/43.abstract N2 - Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691–8.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with atrial fibrillation (AF) at risk for ischaemic stroke, is ximelagatran non-inferior to warfarin in preventing stroke and systemic embolism? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Internal medicine ★★★★★★★ Cardiology ★★★★★★☆ Haematology ★★★★★★★ Design: randomised controlled trial (Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation [SPORTIF]). Allocation: concealed.* Blinding: blinded (outcome assessors).* Follow up: mean 17.4 months. Setting: 259 hospitals, doctor’s offices, and clinics in 23 countries. Patients: 3410 patients ⩾18 years of age who had nonvalvular AF and ⩾1 additional risk factor for stroke: treatment for hypertension but blood pressure <180/100 mm Hg; age ⩾75 years; previous stroke, transient ischaemic attack (TIA), or systemic embolism; left ventricular dysfunction; or age … ER -